Shopping Cart 0
Cart Subtotal
USD 0

ArmaGen Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

ArmaGen Inc (ArmaGen), formerly ArmaGen Technologies Inc is a clinical stage biotechnology company that develops novel therapies for the treatment of neurological disorders. The company's pipeline products include AGT-181, AGT-182, AGT-183, AGT-184, AGT-187, AGT-115, AGT-190, AGT-110 and AGT-160. Its products are used for the treatment of neurological symptoms of lysosomal storage diseases. ArmaGen's products are also used to treat neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's technology platform solution targets recombinant proteins, and therapeutic monoclonal antibodies to the brain. ArmaGen is headquartered in Calabasas, California, the US.

ArmaGen Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ArmaGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

ArmaGen Inc, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

ArmaGen Technologies Raises USD 17 Million In Series A Financing 10

Partnerships 12

ArmaGen Enters into Research Agreement with Rett Syndrome Research Trust 12

Licensing Agreements 13

Shire Enters into Licensing Agreement with ArmaGen for AGT-182 13

ArmaGen Inc-Key Competitors 14

ArmaGen Inc-Key Employees 15

ArmaGen Inc-Locations And Subsidiaries 16

Head Office 16

Recent Developments 17

Corporate Communications 17

Jan 19, 2017: ArmaGen Appoints Mathias Schmidt, Ph.D., as Chief Executive Officer 17

Product Approvals 18

Nov 30, 2017: ArmaGen's AGT-181 Granted Fast Track Designation for the Treatment of Hurler Syndrome (MPS I) 18

Clinical Trials 19

Feb 08, 2018: ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I 19

Feb 16, 2017: ArmaGen Reports Preliminary Evidence of Cognitive Improvement in Children with Hurler Syndrome (MPS I) Treated with AGT-181 21

Feb 07, 2017: ArmaGen Announces Oral Presentation of Preliminary Results from its Phase 2 Clinical Trial of AGT-181 in Patients with MPS 1 to be Presented at WORLDSymposium 2017 22

Appendix 23

Methodology 23

About GlobalData 23

Contact Us 23

Disclaimer 23


List Of Figure

List of Figures

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

ArmaGen Inc, Pharmaceuticals & Healthcare, Key Facts 2

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ArmaGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ArmaGen Inc, Deals By Therapy Area, 2012 to YTD 2018 8

ArmaGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

ArmaGen Technologies Raises USD 17 Million In Series A Financing 10

ArmaGen Enters into Research Agreement with Rett Syndrome Research Trust 12

Shire Enters into Licensing Agreement with ArmaGen for AGT-182 13

ArmaGen Inc, Key Competitors 14

ArmaGen Inc, Key Employees 15

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

ArmaGen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.